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Identity 
Other names: POB1 
HGNC (Hugo): REPS2 
Location: Xp22.2 
Local order: Forward strand: before 16804550-
16862642 CXorf15 (ENSG00000086712) and after 
17300683-17301216. Known pseudogene RP11-
674N8.1 (ENSG00000214321). 




18 exons in REPS2/POB1 gene. 
Transcription 
The transcript length of REPS2/POB1 is 7945 bp. 
REPS2 is not differentially expressed in monozygotic 
twins. Northern blot analysis reveal  
strong expression in rat cerebrum, cerebellum, lung, 
and testis, with weak expression in kidney and no 
expression in heart, thymus, liver, spleen, or adrenal 
gland. Relatively highly expressed in androgen-
dependent as compared to androgen-independent 
prostate cancer cell lines. REPS2/POB1 is down-
regulated during progression of prostate cancer. 
Protein 
Description 
REPS2/POB1, Swiss-Prot Q8NFH8, is expressed as 
two isoforms, the short isoform is 521 residues long, 
while the 660 residues one differs by having a 139 
amino acid extension at the amino-terminus. The most 
prominent structural/functional features, which are 
common to both isoforms, include an amino-terminal 
EH (Eps15 homology) domain, a central region 
containing two adjacent proline-rich regions and a 
carboxy-terminal portion mediating the binding to 
RalBP1.  
 
REPS2/POB1: synopsis of protein structure, interactors, functions. 
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In the figure (not in scale), are described the main 
motifs and domains of the long isoform of 
REPS2/POB1, the interacting proteins and the cellular 
functions, that are described in the text. 
Expression 
The POB1 mRNA is expressed in cerebrum, 
cerebellum, lung, weakly in kidney, and testis (Ikeda et 
al., 1998). It is relatively highly expressed in androgen-
dependent as compared to androgen-independent 
prostate cancer cell lines and xenografts and it is down-
regulated during progression of prostate cancer 
(Oosterhoff et al., 2003). 
Localisation 
REPS2/POB1 localizes in the cytosol, in different sub 
cellular compartments: it colocalizes with clathrin CHC 
in coated pits, with CD63 in late endosomes, with 
GM130 in golgi and with LAMP2 in lysosomes. 
Localization is not EGF dependent and POB1 doesn't 
localize with EEA1 in early endosomes (Tomassi et al., 
2008). 
Function 
REPS2/POB1 is part of a protein complex that 
regulates the endocytosis and down regulation of 
growth factor receptors. Its expression can negatively 
affect growth factor signaling. Multiple transcript 
variants encoding different isoforms have been found 
for this gene and posttranslational modifications have 
been described, such as phosphorylation of Ser493 and 
Ser549 (Oppermann et al., 2009). The REPS2/POB1 
has two amino-terminal EH domains. The structure of 
the second EH domain that extends from 265 to 367 
has been solved by NMR and consists of two EF-hand 
structures, and the second one binds a calcium ion 
(Koshiba et al., 1999). The EH domain binds epsin, 
Eps15 and NF-kappaB p65, and it is associated to 
endocytosis and apoptosis. The central proline rich
region of POB1/REPS2 binds to 14-3-3, amphiphysin 
II and Grb2 and it is associated to receptor 
downregulation and signaling. The carbossi-terminal 
proline rich binds PAG2 and influences paxillin 
localization in focal adhesion. POB1 C-terminus (514-
660) directly interacts with a GTPase activating protein 
that functions downstream of the small G protein Ral, 
RalBP1. Their interaction induces apoptosis. 
REPS2 downregulates receptor signaling and 
endocytosis: REPS2/POB1 interacts with Eps15, epsin 
EPN1, 14-3-3 isoforms, Grb2, amphiphysin 
The presence of EH domains in REPS2/POB1 is 
symptomatic of a role of this gene in receptor 
endocytosis. In fact, REPS2/POB1 EH domain binds to 
Eps15 and to epsin that are both proteins present in 
clathrin-coated pits, involved in receptor endocytosis 
and receptor down regulation. The EH domain interacts 
specifically with the three Asn-Pro-Phe (NPF) motifs in 
the C-terminal region of epsin and their binding 
regulates receptor-mediated endocytosis (Morinaka et 
al., 1999). 
Augmented expression of full-length POB1 in A431 
cells does not affect either binding or internalization of 
EGF, on the contrary, over-expression of either the EH 
domain or the C-terminal region of REPS2/POB1 
affects the ligand dependent internalization pathway of 
EGF and insulin without interfering with the 
constitutive transferrin pathway (Nakashima et al., 
1999).  
Santonico et al. have demonstrated that the EH domain 
of REPS2/POB1 binds Eps15 through an 
unconventional recognition specificity, since it binds to 
both NPF and DPF (Asp-Prp-Phe) motifs. The region 
of Eps15 responsible for the interaction with the EH
domain of REPS2/POB1 maps within a 18 amino acid 
peptide (residues 623-640) that includes three DPF 
repeats. Accordingly, the authors identify a cluster of 
solvent exposed Lys residues, which are only found in 
the EH domain of REPS2/POB1, and influence binding 
to both NPF and DPF motifs (Santonico et al., 2007). 
RalBP1, REPS2/POB1, epsin, and Eps15 form a 
complex with alpha-adaptin of AP-2 in Chinese 
hamster ovary cells and this complex is reduced in 
mitotic phase, when REPS2/POB1 and epsin are found 
phosphorylated. They are both phosphoryated by p34 
cdc2 kinase, in vitro. POB1 is found phosphorylated in 
Ser551 and Ser493, in vivo. Phosphorylation of epsin 
in Ser 357 inhibits binding to POB1, causing 
disassembly of the complex, thus inhibiting receptor 
mediated endocytosis (Kariya et al., 2000). This data 
explains the contribution of the EH domain of POB1 to 
the formation of a protein complex that favours 
receptor internalization and that it is dismantled in 
mitosis. It is suggested that EGF stimulation induces 
also tyrosine-phosphorylation of POB1 and subsequent 
formation of a EGFR-POB1 complex in COS cells 
(Ikeda et al., 1998).  
REPS2/POB1 shorter isoform2 is downregulated 
during human prostate cancer progression from 
androgen-dependent to androgen-independent 
(Oosterhoff et al., 2003). It was observed that a high 
level of REPS2 correlates with reduced EGF-
internalisation and signaling since the induced 
expression of REPS2 exerts an inhibiting effect on 
several EGF-responsive genes (EGF-receptor, EGR-1, 
Fos and Jun) (Oosterhoff et al., 2005). Accordingly, 
increased expression of POB1 isoform 2 correlates with 
a decrease of EGF-induced phosphorylation of Erk1-
Erk2 and Shc (Tomassi et al., 2008).  
From these experiments, it can be concluded that 
increased REPS2/POB1 expression negatively affects 
EGF receptor internalisation and subsequent signaling. 
Therefore, the decreased REPS2 expression observed 
during prostate cancer progression, results in enhanced 
EGF receptor expression and signaling, which could 
add to the androgen-independent state of advanced 
prostate cancer. 
The central region of REPS2/POB1 plays a regulatory 
role in epidermal growth factor receptor endocytosis  
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and signaling. Overexpression of the central region of 
POB1 (447-504), inhibits EGF endocytosis, titrating 
essential proteins away, thus depauperating the receptor 
down-regulation machinery. In fact, this region of 
POB1/REPS2 plays its regulatory role in EGFR 
endocytosis by binding: (i) to 14-3-3 proteins in a 
phosphorylation dependent way (i.e., phospho-Ser493 
of POB1), (ii) to the C-SH3 domain of Grb2 and (iii) to 
the SH3 of amphiphysin II. The target of the SH3 
domain of amphiphysin and of the carboxy-terminal 
SH3 of Grb2 is a short peptide flanking Arg483 in 
POB1. These interactions are not EGF dependent and 
are probably exclusive, since the binding motifs are
only nine amino acids apart. These findings suggest 
that 14-3-3 could work by bridging the EGF receptor 
and the scaffold protein POB1/REPS2. The 14-3-3 
binding motif HSRASSLD, flanking the Ser493 of 
POB1, is conserved in the mouse orthologs and in the 
14-3-3 binding motif that flanks the Ser510 of human 
REPS1 protein, found phosphorylated in vivo in A431 
cells (Stover DR et al. Phosphosite). The POB1 Ser493 
is predicted to be phosphorylated by Akt. In agreemnt, 
when cells are treated with PI3K/Akt inhibitor 
wortmannin, 14-3-3 binding to REPS2/POB1 is 
abolished (Tomassi et al., 2008). The 14-3-3 zeta has 
already been reported as associating with the EGFR, 
epidermal growth factor receptor, cytoplasmic tail and 
co-localizing along the plasma membrane with EGFR 
upon EGF stimulation (Jin et al., 2004). Thus a 14-3-3 
dimer could bridge REPS2/POB1 to the EGFR upon 
EGF induction. 
Cell migration and paxillin localization: REPS2/POB1 
antagonises PAG2/ASAP1 
POB1 forms a complex with PAG2/ASAP1 in intact 
cells. PAG2 is a paxillin-associated protein with ADP-
ribosylation factor GTPase-activating protein activity, 
also called ASAP1 (ArfGAP with SH3 domain, ankyrin 
repeat and PH domain UniProtKB: Q9ULH1). The 
SH3 of PAG2 binds the proline motif (562PSKPIR567) 
at the carboxyl-terminal region of POB1. This motif is 
essential for PAG2-POB1 interaction since substitution 
of the two proline residues with alanines in mutant 
POB1(PA), impaired its binding to PAG2. POB1 may 
therefore form a complex with paxillin through PAG2. 
Paxillin is a focal adhesion-associated scaffolding 
protein that recruits signaling molecules to the focal 
adhesions and forms protein complexes that coordinate 
signaling, cell spreading and motility. PAG2 
overexpression causes loss of endogenous paxillin 
recruitment to focal contacts and also impaires cell
migratory activities. The ability to suppress fibronectin-
dependent migration depends on the ArfGAP domain 
of PAG2, but not on the POB1-binding domain, of 
PAG2. On the other end, POB1, but not POB1(PA), 
can suppress the inhibitory action of PAG2 on paxillin 
localization to focal adhesion (Oshiro et al., 2002). 
These results suggest that POB1, by binding to PAG2, 
suppresses the inhibitory action of PAG2 on the 
paxillin recruitment to focal contacts. This suggests that 
POB1 may function as a scaffold protein that interacts 
with proteins involved in endocytosis and migration, 
thus regulating signaling and motility. PAG2/ASAP1 
gene was found associated with prostate cancer 
metastasis since it is up-regulated in a human 
metastatic prostate subline and immunohistochemistry 
of xenograft sections show a significantly strong 
cytoplasmic ASAP1 protein staining in tumor-
nonmetastatic PCa2 tissue, compared to a non-staining 
in benign tissue, and an even stronger staining in PCa1-
metastatic tissue. Moreover, additional ASAP1 gene 
copies are detected in 58% of the primary prostate 
cancer clinical specimens. A small interfering RNA 
reducing ASAP1 protein expression, can suppress in 
vitro PC-3 cell migration and matrigel invasion. 
Therefore PAG2/ASAP1 represents a therapeutic target 
and a biomarker for metastatic disease (Lin et al., 2008) 




- S324F, cds mutation 971C>T heterozygous in 
glioblastoma multiforme (Parsons et al., 2008). 
- V67M, cds mutation 199G>A homozygous in 
malignant melanoma. 
- No high level gene amplification (>7), 1 homozygous 
deletion in breast cancer, 559 LOH (Loss of 
Heterozygosity). 
Implicated in 
Non-small cell lung cancer (NSLC) and 
prostate cancer 
- Apoptosis in non-small cell lung cancer (NSLC) and 
prostate cancer: REPS2 binds and inhibits RalBP1. 
Ikeda et al. (1998) cloned POB1 (partner of Ralbp1) as 
the first known binding partner of Ralbp1 by the yeast 
two-hybrid method using Ralbp1/RLIP76 as bait and 
clearly demonstrated specific binding and complex 
formation between Ralbp1 and REPS2/POB1. The 
binding to RalBP1 did not affect the GTPase activating 
activity of RalBP1. The interaction of POB1 with 
RalBP1 induces cell death in human prostate cancer 
cell ines LNCaP-FGC and LNCaP-LNO. Oosterhoff et 
al. show that REPS2/POB1-induces apoptosis in 45% 
of transfected cells, within 48 hours. When prostate 
cancer cell lines are transfected with a deletion mutant 
of REPS2/POB1, lacking the RalBP1 binding domain, 
only 30-40% of the transfected cells became apoptotic 
after 72-96 hours (Oosterhoff et al., 2003). 
REPS2/POB1 (514-660) binds RalBP1 C-terminal 
amino acids, 499-655, while an almost overlapping 
region of RalBP1 (440-655) binds the heat shock factor 
1 Hsf-1 (Hu and Mivechi, 2003). Shingal et al. show a 
ternary complex formation between RalBP1, Hsf-1, and
REPS2/POB1. RalBP1, Hsf1, HSP90 and tubulin make 
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a complex in cell (Singhal et al., 2008). Hsf-1 and 
REPS2/POB1 induce drug sensitivity and apoptosis by 
inhibiting RalBP1. 
Binding of REPS2/POB1 to RALBP1 inhibits the 
transport activity of the Ral-binding nucleotidase, 
which functions as an energy-dependent transporter for 
GSH-conjugates as well as unrelated xenobiotics. 
RALBP1 (RLIP76) is the major transporter of the 
anthracycline antibiotic, doxorubicin, which is one of 
the most widely used anticancer drugs (Singhal et al., 
2007). Therefore, REPS2/POB1 is a specific and 
saturable inhibitor of the glutathione-electrophile 
conjugates and of the doxorubicin transport activity of 
RalBP1. Yadav et al. show that REPS2/POB1 can 
regulate the transport function of RalBP1/RLIP76 and, 
in agreement with previous studies, show that 
inhibition of RalBP1 induces apoptosis in cancer cells 
through the accumulation of endogenously formed 
GSH-conjugates (Yadav et al., 2005). Hence, 
REPS2/POB1 over-expression inhibits RalBP1-
mediated transport of glutathione-conjugates thus 
promoting apoptosis and can influence drug-efflux 
mechanisms that cause resistance to cancer treatment. 
Hsf-1 also causes specific and saturable inhibition of 
the transport activity of RalBP1. The combined 
augmentation of Hsf-1 and REPS2/POB1 causes nearly 
complete inhibition of RalBP1 and a dramatic 
apoptosis in NSLC (non-small cell lung cancer) cell 
line H358 through Ralbp1 binding (Singhal et al., 
2008). The marked apoptotic effect caused by the 
increase of Hsf-1 and REPS2/POB1 in lung cancer 
cells, suggests a novel targeted therapy in which 
liposomally encapsulated Hsf-1 and POB1 could be 
used clinically as a therapeutic agent. 
- Apoptosis in prostate cancer cells: REPS2/POB1 
counteracts the apoptosis inhibitor NF-kappaB p65 
The NF-kappaB subunit p65 is identified as a human 
REPS2/POB1 protein partner, since the NPF-motif in 
p65 acts as binding site for the EH domain in REPS2. 
However, in cultured prostate cancer cells, the REPS2-
p65 interaction is triggered upon stimulation with the 
phorbol ester, phorbol-12-myristate-13-acetate (PMA). 
During prostate cancer progression from androgen-
dependent to androgen-independent growth, the 
observed downregulation of REPS2 is accompanied by 
upregulation of NF-kappaB activity, that inhibits 
apoptosis (Penninkhof et al., 2004). Hence, the authors 
suggest that a decreased expression of REPS2 might be 




Doolan et al. (2009) suggest that REPS2 mRNAs may 
be useful as favourable prognostic and predictive 
markers for breast cancer. Univariate and multivariate 
analyses were used to identify associations between 
expression of these transcripts and patients' 
clinicopathological and survival data. 
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